Admittance Technologies has received $3.9 million in funding, according to a filing with federal regulators.
The Austin-based startup raised the money from 15 unidentified investors on June 26th, according to its filing with the U.S. Securities and Exchange Commission.
The startup, founded in 2010, created the CardioVol technology platform to measure blood volume using a pacemaker to detect disease and treat patients with the devices. Dr. Marc Feldman, its founder, serves as professor in biomedical engineering at UT Austin and UTSA. He has previously founded two other companies, Setagon and CardioSpectra, both ventures were acquired.
Wes Johnson, a seasoned healthcare executive, serves as its chief executive officer.
In 2013, the company received nearly $2 million in investment from the state’s Emerging Technology Fund.